Acesso livre
Acesso livre

Destaques

Metanálise de estudos clínicos randomizados | Vacinas para prevenir COVID-19.

15 Fev, 2022 | 11:43h

Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials – PLOS One

Revisão sistemática | Eficácia das terapias antivirais para COVID-19.

15 Fev, 2022 | 11:42h

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials – BMC Infectious Diseases

Estudo identifica fatores de risco para Covid-19 grave em crianças.

15 Fev, 2022 | 11:41h

Risk Factors for Severe COVID-19 in Children – Pediatrics

Covid-19 – Quarta dose de vacina: quem precisa dela e por quê?

15 Fev, 2022 | 11:40h

Covid-19: Fourth vaccine doses—who needs them and why? – The BMJ

Nova Classificação Internacional de Doenças (CID-11) da OMS entra em vigor.

14 Fev, 2022 | 16:18h

Comunicado de imprensa: WHO’s new International Classification of Diseases (ICD-11) comes into effect – World Health Organization

Ver também:

ICD-11 Browser

ICD-11 website

ICD-11 coding tool

 

Comentário no Twitter

 

Novavax afirma que vacina proteica funciona para crianças a partir dos 12 anos de idade.

14 Fev, 2022 | 16:16h

Novavax says protein vaccine works for kids as young as 12 – Associated Press

Comunicado de imprensa: Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

Conteúdos relacionados:

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Pfizer e FDA recuam em relação ao plano para agilizar a avaliação de vacinas contra Covid-19 em crianças menores de 5 anos.

14 Fev, 2022 | 16:14h

Pfizer and FDA pull back from plan to expedite review of Covid-19 vaccine in young children – STAT

Ver também:

COVID-19 vaccine for kids under 5 delayed as Pfizer extends trial – CIDRAP

Pfizer postpones FDA request for Covid vaccine for kids under 5 – NBC News

Estudos conflitantes levantam questões sobre se algum anticorpo monoclonal funciona contra a variante “irmã” da Ômicron.

14 Fev, 2022 | 16:13h

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant – STAT

Conteúdos relacionados:

FDA halts use of antibody drugs that don’t work vs. Omicron.

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

Diretriz ERS | Seguimento de “long COVID-19”.

14 Fev, 2022 | 16:11h

European Respiratory Society Statement on Long COVID-19 Follow-Up – European Respiratory Review

Primeira definição para “long Covid” em crianças e jovens é formalmente elaborada.

14 Fev, 2022 | 16:10h

Comunicado de imprensa: First research definition for ‘Long COVID’ in kids and young people formally agreed – BMJ

Artigo original (preprint): Long COVID (Post-COVID-19 condition) in Children: a modified Delphi Process – Archives of Disease in Childhood

Comentários:

Expert reaction to Delphi consensus study on a long-COVID definition in children – Science Media Centre

Long covid: “Holistic” approach is best, given range of symptoms, say researchers – The BMJ

Conteúdos relacionados:

Cohort Study: Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England.

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

Editorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.